# Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts

> **NCT07498205** · PHASE4 · NOT_YET_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 268 (estimated)

## Conditions studied

- Myelofibrosis
- Myelofibrosis (MF)

## Interventions

- **DRUG:** Momelotinib
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07498205
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-08
- **Primary completion:** 2029-08-08
- **Final completion:** 2031-08-08
- **Target enrollment:** 268 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07498205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07498205, "Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07498205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*